EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Case Report: Nephrotic syndrome with minimal change disease during anti-tuberculosis treatment and tiopronin use

Heng Liao, Fei Yan, Xingxia Liu

Frontiers in Medicine · 10.08.2026 · 13

DOI: 10.3389/fmed.2026.1807135 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Medicine, online erschienen am 10.08.2026. Verfasst von Heng Liao und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Fourth People's Hospital of Chengdu, Chengdu, China. Die Arbeit nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hepatoprotective agents are often added during prolonged anti-tuberculosis (anti-TB) therapy, and medication-associated nephrotic syndrome may be under-recognized. Case A 31-year-old man with pulmonary tuberculosis received long-term anti-TB therapy (rifapentine, isoniazid, and ethambutol) and continuous tiopronin (0.2 g three times daily). He developed edema, foamy urine, and oliguria. Pre-admission tests showed proteinuria (3+), serum albumin 19.6 g/L, and serum creatinine 161 μmol/L. On admission, urine protein was 4+, serum albumin 20.6 g/L, serum creatinine 142.9 μmol/L, and estimated glomerular filtration rate (eGFR) 58.86 mL/min, with hyperlipidemia. Kidney biopsy confirmed minimal change disease (MCD). Interventions and outcome All anti-TB drugs and tiopronin were discontinued, and tacrolimus was initiated after biopsy. Anti-TB therapy was reintroduced as isoniazid monotherapy. Renal function improved rapidly (serum creatinine 55 μmol/L; eGFR 128.1 mL/min at discharge), and dipstick proteinuria became negative on short-term follow-up. The tacrolimus trough concentration was 3.6 ng/mL.

Conclusion

The improvement after withdrawal of multiple suspected agents and continued recovery after reintroduction of isoniazid alone support a drug-associated etiology, but do not allow definitive attribution to a single causative drug. Routine renal monitoring should accompany hepatoprotective add-on therapy during anti-TB treatment.

Schlagwörter

Stichwörter der Autor:innen

anti-tuberculosis therapydrug withdrawaldrug-associated kidney diseaseminimal change diseasenephrotic syndrometacrolimus therapeutic drug monitoringtiopronin

Autor:innen und Institutionen

  • Department of Pharmacy, The Fourth People's Hospital of Chengdu, Chengdu, China.
  • Department of Clinical Laboratory, The Clinical Hospital of Chengdu Brain Science Institute, MOE Key Lab for Neuroinformation, University of Electronic Science and Technology of China, Chengdu, China.
  • Department of Clinical Laboratory, The Fourth People's Hospital of Chengdu, Chengdu, China.
  • Department of Pharmacy, Sichuan Provincial People's Hospital, Chengdu, China.

Zitieren

APA

Liao, H., Yan, F., & Liu, X. (2026). Case Report: Nephrotic syndrome with minimal change disease during anti-tuberculosis treatment and tiopronin use. Frontiers in Medicine, 13. https://doi.org/10.3389/fmed.2026.1807135

Vancouver

Liao H, Yan F, Liu X. Case Report: Nephrotic syndrome with minimal change disease during anti-tuberculosis treatment and tiopronin use. Frontiers in Medicine. 2026;13. doi:10.3389/fmed.2026.1807135

BibTeX
@article{Liao2026,
  author = {Liao, Heng and Yan, Fei and Liu, Xingxia},
  title = {Case Report: Nephrotic syndrome with minimal change disease during anti-tuberculosis treatment and tiopronin use},
  journal = {Frontiers in Medicine},
  year = {2026},
  volume = {13},
  doi = {10.3389/fmed.2026.1807135}
}
Kostenlos starten →